Cyclic AMP-Specific Pdes: a Promising Therapeutic Target For

Mini-Review • DOI: 10.2478/v10134-010-0012-0 • Translational Neuroscience • 1(2) • 2010 • 101–105 Translational Neuroscience CYCLIC AMP-sPECIFIC PDEs: A PROMISING THERAPEUTIC Mousumi Ghosh TARGET FOR CNS REPAIR Damien D. Pearse* The Miami Project to Cure Paralysis, University of Miami School of Abstract Medicine, Research to date has indicated that cAMPspecific PDEs, particularly the members of PDE4 family, play a crucial Miami, FL 33136, USA. role in the pathogenesis of CNS injury and neurodegeneration by downregulating intracellular levels of cAMP in various cell types. Reduced cAMP signaling results in immune cell activation, inflammation, secondary tissue damage, scar formation and axon growth failure, ultimately leading to an exacerbation of injury, the prevention of endogenous repair and limited functional recovery. Although inhibition of cAMPspecific-PDE activity through the use of drugs like Rolipram has been shown to reverse these deficiencies and mediate neurorepair, an inability to develop selective agents and/or reduce dose-limiting side-effects associated with PDE4 inhibition has hampered their clinical translation. Recent work with more selective pharmacological inhibitors of cAMP-specific PDEs and molecular targeting approaches, along with improved understanding of the basic biology and role of PDEs in pathological processes may enable this promising therapeutic approach to advance clinically and have a similar impact on CNS injury and disease as PDE5 inhibitors have had on the treatment of sexual dysfunction. Keywords Phosphodiesterase • cyclic AMP • Rolipram • CNS repair • SCI • TBI Received 17 March 2010 © Versita Sp. z o.o. accepted 23 March 2010 1. Introduction to date, which vary in cyclic nucleotide PDE7s’ respective proteins has not yet been The second messenger cyclic adenosine specificity, affinity, regulatory control and reported. PDE8B mRNA has been shown to be monophosphate (cAMP), first discovered in subcellular compartmentalization, there are present in the hippocampus and is elevated 1957 by Sutherland and colleagues [1], is an eight PDE gene families that are capable of in patients with late-stage Alzheimer’s disease important second messenger involved in hydrolyzing cAMP, some of which hydrolyze [12]. However, as both PDE7 and PDE8 are intracellular signaling for a diverse range of cAMP exclusively and others both cAMP and cAMP-degrading PDEs, exhibiting 10- and 40- physiological events from cell proliferation cGMP [2,5]. In the central nervous system fold higher affinity than PDE4 respectively, it and survival to differentiation and plasticity. (CNS), under normal physiological conditions, has led to speculation that these enzymes are Cellular cAMP concentrations are determined basal levels of cAMP degrading PDE4 have largely involved in the regulation of basal (or by synthesis (adenylyl cyclases) and hydrolysis been shown within various regions of the brain low concentrations) versus stimulated levels of (cAMP-specific phosphodiesterases). PDEs and spinal cord, such as in the cerebral cortex, cAMP. Further studies are needed to examine are the only known negative regulators of hippocampus, hypothalamus, striatum and basal protein levels of PDE7 and 8 isoforms in cAMP, participating in the fine tuning of cyclic the substantia nigra, both in neurons and glia; the CNS and to determine how they are altered nucleotide mediated signaling by controlling 6-8. For the other cAMP-specific PDEs; PDE7 after CNS injury and disease [13]. the rate of degradation of cAMP and cyclic and 8, high mRNA expression of both PDE7A In the acute phase of CNS injury, guanosine monophosphate (cGMP) [2]. The and PDE7B are seen in the rat brain. PDE7A is subsequent to mechanical trauma, various association of PDEs with specific anchoring found in the olfactory bulb and tubercle, the degenerative processes including neuron and proteins, A kinase anchoring proteins (AKAP) hippocampus, particularly the granule cells oligodendrocyte cell death, axon axotomy and protein kinase A (PKA), within distinct of the dentate, and several brainstem nuclei and demyelination as well as the formation of subcellular domains, allows compartmentalized [9] while the highest amount of PDE7B mRNA cellular reactivity at the injury site contribute cyclic nucleotide signaling [3-4] in response to expression is observed in the cerebellum, to loss of neurological function and abortive specific extracellular stimuli. From 11 different striatal complex and the dentate gyrus of the endogenous repair [14]. Tissue levels of PDE families that have been characterized hippocampus [10-11]. The production of the cAMP have been shown to be reduced in * E-mail: [email protected] 101 Translational Neuroscience experimental animal models of both traumatic ameliorated if PDE4 activity is antagonized [15- of the injury after SCI [31]. Supporting evidence brain [15-16] and spinal cord injury (TBI or 16, 18]. for the role of PDE4 in apoptotic signaling, an SCI; 16). These levels can be largely restored There are four genes that encode different important mechanism of secondary injury and the detrimental effects of injury partially PDE4 enzymes, of which PDE4A, B and D, post-SCI, also comes from studies that have reversed when the PDE4-specific inhibitor but not C, are expressed within the CNS examined cellular injury in vitro using primary Rolipram is given. [15-16]. Members of the [7]. Although there are a number of PDE4 neuronal cultures. The aberrant stimulation PDE4 family have been found to play a key gene families and long and short isoforms, of cell cycle proteins, such as cyclin D1, and role in initiating neuroinflammation [15-17], generated through alternative splicing, the activation of death-signaling caspase 3 accelerating secondary tissue damage [18] methods for antagonizing PDE4 activity after cellular injury, could be attenuated by and restricting the intrinsic ability of injured have been non-specific as the majority of treatment with specific PDE inhibitors such as neurons to regenerate [16,19] and/or be experimental studies have used the general vinpocetine (PDE1 inhibitor), trequinsin (PDE3 remyelinated [16]. The involvement of cAMP- PDE4 inhibitor, Rolipram, or pharmacological inhibitor), and rolipram (PDE4 inhibitor) when PDEs in these deleterious events makes them agents with a similar profile. Thus it has been delivered in a concentration-dependent a promising therapeutic target for neurorepair difficult to identify PDE4 gene and isoform- manner [35]. From these in vivo and in vitro and restoration of function. The current review specific roles in CNS pathophysiology from investigations it is evident that targeting describes the regulation of cAMP-specific PDEs these investigations. Therefore, in the ensuing PDEs produces potent anti-inflammatory and following traumatic injury to the CNS and review of the therapeutic potential of PDE4 neuroprotective effects within the injured CNS. surveys the use of cAMP-PDE specific inhibitors inhibition for CNS injury protection and as a therapeutic approach to prevent tissue repair, the exact PDE4 gene that is targeted 1.3. PDE4 inhibition for damage, promote neuroregeneration and is lacking, without the availability of more neurogeneration enhance functional outcome. specific pharmacological agents or molecular Previous work with Rolipram from our group approaches for PDE4 inhibition. and others [15-16] provides strong evidence 1.1. Regulation of cAMP-specific PDEs for a negative role of PDE4 isozymes in in the CNS following injury 1.2. cAMP specific PDE inhibition for restricting endogenous neuroregeneration Since cAMP-specific PDE activity in CNS tissue cytoprotection following CNS injury. The reversal of injury- was first identified several decades ago, high Central to the cytoplasmic effects of cAMP– induced reductions in cAMP levels in the brain isozyme expression levels for PDEs 1, 2, 4, and specific PDE inhibitors is the potent anti- and spinal cord after SCI with the combinatory 10 have been reported in specific areas of the inflammatory action of cAMP signaling. administration of Rolipram and a cAMP analog brain and the spinal cord following injury [7]. Rolipram and other PDE4 inhibitors have can promote significant supraspinal axon The activity of these PDE’s may be responsible been demonstrated to block neutrophil and growth across the injured spinal cord [16]. for lowering intracellular levels of cyclic macrophage recruitment to the site of injury Studies have demonstrated that an elevation nucleotides, stimulating in turn the migration [29-30], to reduce mononuclear phagocyte of cAMP in vitro allows axons to grow over and activation of various immune cell activation [31-32] and to decrease production inhibitory substrates [36] and is important populations; neutrophils, macrophages, and of proinflammatory cytokines, such as TNF-α, for axon guidance and turning behaviors microglia [20-23], impairing blood brain barrier IL-1β and IL-6 [15-16] while enhancing [37]; conversely, decreases in cAMP levels function and/or reducing neuronal activity and expression of suppressor cytokines, like IL-10 are thought to occur during development, suppressing survival programs important for [31]. These actions are desirable in the acutely reducing intrinsic neuronal growth capacity preventing cell death [21]. injured CNS as immune cell activation and and restricting plasticity in the adult organism. Though neurons express multiple PDEs, ensuing inflammation is a primary mediator of Gao and colleagues

Load more